Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Beckman Coulter Diagnostics’ boothBeckman Coulter Diagnostics’ booth showcased its portfolio of high-productivity analytical and workflow systems. Solutions featured in the booth included the Power Express automation solution, the new DxH Connected Workcell, and IRIS International urinalysis solutions for automated urinalysis.
The Binding Site announced the formation of its new Immunologicals Group. Formerly known as OEM, this new team will have a broad remit to encompass the sales, marketing, and support of specialist antibodies, antigens, disease state sera, and services to IVD manufacturers, research scientists, and academic facilities.
BioMérieux announced the FDA 510(k) clearance and commercial availability of Vidas 3, the new generation of Vidas. Vidas 3 features enhanced automation, in particular the preanalytical section from the barcoded primary tube including dilution, improved traceability, and new software capabilities, as well as a quality control program in compliance with laboratory certification standards. Vidas 3 is CE marked and registered at the Chinese Food and Drug Administration.
EKF Diagnostics launched its Altair 240 clinical chemistry analyzerEKF Diagnostics launched its Altair 240 clinical chemistry analyzer, a benchtop platform that is EKF’s first fully integrated chemistry system for the global market. The fully automated system has LIS bidirectional connectivity, and double arm functionality yields up to 480 tests per hour.
ELITechGroup Molecular Diagnostics Precision System Science and announced the upcoming CE-IVD marking of ELITe InGenius for IVD applications in Europe and the expected availability of the instrument as laboratory use equipment in the U.S.
Roche introduced next-generation diagnostic testing platforms and an educational initiative that demonstrates how it’s partnering with customers to redefine the value of the laboratory.
The FDA has approved the Siemens Advia Centaur HIV Ag/Ab Combo (cHIV) assay. This latest addition to the Advia Centaur infectious disease menu, which also includes tests for hepatitis A, B, and C, eHIV, syphilis, and other infectious disease assays, enables laboratories to further consolidate their testing to enhance efficiencies.
Easy Billing announced the newest version of Easy Billing Professional medical billing software. This version features a simple process for storing ICD-9 to ICD-10 crosswalk codes for viewing and selection along with code alerts and discontinued codes.
The Leica DM2500 LED is suitable for clinical laboratories and for research applications in microbiology, developmental biology, cytology, zoology, botany, and more. The ultra-bright LED illumination of the DM2500 LED offers a constant color temperature at all light intensities, enabling particularly fine differentiation of colors in stained specimens.
QuantuMDx explored licensing opportunities for its rapid DNA extraction kit Q-PREP at BIO in Philadelphia, which took place in mid-June. Q-PREP is a next-generation DNA extraction technology set to dramatically shorten and simplify the molecular workflow for polymerase chain reaction, sequencing, and other molecular processes. The technology is presently being deployed in next-generation spin columns.
